Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.

Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.